With over 40% of all medicines in the pipeline aimed at rare diseases, the future looks positive for increasing the number of treatments available. However, as Ben Hargreaves discovers, research ...

Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

Bayer's quest to revamp its drug discovery engine continues apace, with the company's recently acquired Vividion subsidiary forging an alliance with Tavros Therapeutics, aimed at finding new drug ...

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The two partners ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Nanoscope Therapeutics is on the brink of filing what could be the first mutation-agnostic gene therapy for incurable eye disease retinitis pigmentosa.

Biofourmis has raised $300 million in fourth-round financing, sending its value rocketing to around $1.3 billion and injecting some fresh momentum into the digital health sector after a slowdown ...

Nordic Nanovector's plan to emerge from its current troubles by merging with APIM Therapeutics has hit an insurmountable hurdle – in the shape of its own shareholders. The troubled Norwegian ...

Endo International is the latest drugmaker to file for chapter 11 bankruptcy protection in connection with opioid litigation in the US, after agreeing a $6 billion deal with creditors that ...

Amgen and AstraZeneca haven't won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but the ICER in the US maintains it will probably not be ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

US district court grants an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata.